This trial is evaluating whether Indapamide Pill will improve 1 primary outcome and 5 secondary outcomes in patients with Secondary Progressive Multiple Sclerosis (SPMS). Measurement will happen over the course of Change in Timed 25-Foot Walk performance between the 6 month and 18 month visit.
This trial requires 35 total participants across 1 different treatment group
This trial involves a single treatment. Indapamide Pill is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The pathogenesis of primary progressive or relapsing-remitting multiple sclerosis is still unknown. Nonetheless, this study demonstrates that in secondary progressive multiple sclerosis, immunomodulatory therapies may be an effective option to prevent relapse, which is frequently associated with rapid progression." - Anonymous Online Contributor
"Secondary progressive MS is defined by progressive neurological loss over time, which leads to persistent disability, even when the course of the disease is relatively mild. The course of spms is similar to classical progressive MS, with lesions more often appearing at the onset of symptoms, expanding and worsening, and resulting in disability more quickly. Spms patients have poorer outcomes compared with patients in the classic form of MS, mainly due to reduced time to dissemination. We suggest that patients with spms need to be monitored carefully because of the risk of developing secondary progressive MS of their own, even when they do not have another clinical form of MS." - Anonymous Online Contributor
"It is important to understand the disease process, like remission and spoliation in both primary and secondary progressive multiple sclerosis, as such information, can help with the selection of treatment, to define the disease-free era as well as assessing treatment effects and to monitor disease progression. Patients with SPMS are the most difficult to treat in terms of progression and quality of life." - Anonymous Online Contributor
"A limited number of treatments are available for RRMS and SPMS patients. Several treatments are useful for RRMS patients but only palliative care has a positive effect on QOL in SPMS." - Anonymous Online Contributor
"The prognosis of secondary progressive MS can be improved by active treatment with a specific disease-modifying antirheumatic drug or immunomodulators. More recent experience confirms sustained remission after 3 to 12 years with such treatment." - Anonymous Online Contributor
"Results from a recent clinical trial indicates that the incidence of secondary progressive multiple sclerosis in the United States appears to be increasing with a significant proportion of individuals with secondary progressive multiple sclerosis under diagnosed or undertreated." - Anonymous Online Contributor
"New dosage forms are undergoing clinical trials, which will assist in the development of an improved, safer indapamide formulation for therapeutic use. Clinically, indapamide is a safer treatment option for MS, especially in secondary progressive MS patients with concomitant hypertension." - Anonymous Online Contributor
"Overall only 18 out of the 743 cases of spms were familial. Of the other 506 cases, there were only 2 cases that could be linked to environmental factors, and 2 cases with unknown causes. In the familial cases there was a high susceptibility of presenting with the same clinical characteristics of spms, and a similar relapse rate as seen in the sporadic cases, showing that it could be the same disease. In any case, it is important to remember that in the epidemiology, spms is a multifactorial disease, and this must be taken into account when analyzing the results of any clinical or epidemiological study." - Anonymous Online Contributor
"Indapamide pill was frequently used in combination with other drugs in SPMS patients. Further studies are needed to investigate the influence of indapamide on other drugs' tolerability, efficacy and side effects." - Anonymous Online Contributor
"Although no treatment has been proven to halt the progression of secondary progressive multiple sclerosis, the development of new treatments is ongoing. The following are some of these new treatments and their benefits:\n\n- Natalizumab is a monoclonal antibody therapy that binds to the α4 integrin subunit on T cells, interfering with their binding to their receptors. Results from three large randomized, placebo-controlled, double-blind trials demonstrated that natalizumab had a significant therapeutic effect on reducing relapses in patients with secondary progressive multiple sclerosis. Patients who take the drug experienced a 50% reduction in relapses versus patients who did not." - Anonymous Online Contributor
"Results from a recent paper, it was found that indapamide does not improve either the symptom profile or the cognitive functioning of patients with secondary progressive multiple sclerosis." - Anonymous Online Contributor
"There is a lack of well-designed clinical trials for secondary progressive multiple sclerosis (spms). There is an urgent need for these clinical trials to improve the treatment for spms." - Anonymous Online Contributor